Capital Ideas Media publisher Mark Bunting sits down with Dr. Jack Regan, founder and CEO of Lexagene Holdings (TSXV:LXG;OTC:LXXGF). The company is on the verge of commercializing its pathogen detection system, which is faster and less expensive than current methods.

Regan says Lexagene has already had exploratory talks with larger biotech firms that need this technology in their product line. That makes a buyout of Lexagene later this year a distinct possibility.